Clinical research in the competence network "acute and chronic leukemias";Klinische forschung im kompetenznetz "akute und chronische leukämien"

Internist

Volumn 45, Issue 4, 2004, Pages 384-392

  Hehlmann, R ^a   Berger, U ^a   Aul, C ^b   Buchner T ^c   Dohner H ^d   Ehninger, G ^e   Ganser, A ^f   Hoelzer, D ^g   Gokbuget N ^g   Uberla K ^h  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b ST JOHANNES HOSPITAL   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d UNIVERSITY HOSPITAL ULM   (Germany)

^e UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g GOETHE UNIVERSITY   (Germany)

^h UNIVERSITY OF MUNICH   (Germany)

Author keywords

Acute leukemia; Chronic leukemia; Information and communication structures; Interdisciplinary cooperation; Study groups; Treatment optimization

Indexed keywords

ACUTE LEUKEMIA; CHRONIC LEUKEMIA; CLINICAL RESEARCH; COMMUNITY HOSPITAL; COMPETENCE; CONFERENCE PAPER; EUROPEAN UNION; GERMANY; MEDICAL SPECIALIST; SURVIVAL; UNIVERSITY HOSPITAL;

ACUTE DISEASE; BIOMEDICAL RESEARCH; CHRONIC DISEASE; CLINICAL TRIALS; COOPERATIVE BEHAVIOR; GERMANY; GOVERNMENT PROGRAMS; HUMANS; INFORMATION DISSEMINATION; INTERINSTITUTIONAL RELATIONS; LEUKEMIA; MEDICAL ONCOLOGY; PHYSICIAN'S PRACTICE PATTERNS; PROFESSIONAL COMPETENCE; QUALITY OF HEALTH CARE; TECHNOLOGY TRANSFER;

EID: 2942612499     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-004-1151-5     Document Type: Conference Paper

References (12)

1. Bloomfield CD, Lawrence D, Byrd JC et al. (1998) Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58: 4173-4179
2. Büchner T, Hiddemann W, Wormann B et al. (1999) Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-Thioguanine: a randomized trial by the German AML Cooperative Group. Blood 93: 4116-4124
3. Degos L, Dombret H, Chomienne C et al. (1995) All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 85: 2643-2653
4. Druker BJ, Talpaz M, Resta DJ et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031-1037
5. Gallo RC (1981) Growth of human normal and leukemic T cells: T-cell growth factor (TCGF) and the isolation of a new class of RNA tumor viruses (HTLV). Blood Cells 7: 313-329
6. Hehlmann R (2001) Significance of networking for clinical research in the future. Onkologie 24: 380-384
7. Hehlmann R, Berger U, Pfirrmann M et al., German CML-Study Group (2003) Randomized comparison of interferon α and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon α and hydroxyurea. Leukemia 17: 1529-1537
8. Hochhaus A, Hehimann R (Hrsg) (2001) Chronische myeloische Leukämie. Biologie, Diagnostik, Klinik, Therapie. Uni-Med, Bremen
9. Hoelzer D, Gökbuget N, Digel W et al. for the GMALL Study Group (2002) Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for ALL. Blood 99: 4379-4385
10. Nowell PC, Hungerford DA (1960) A minute chromosome in human chronic granulocytic leukemia. Science 132: 1497-1501
11. Pinkel D (1979) The ninth annual David Karnofsky Lecture. Treatment of acute lymphocytic leukemia. Cancer 43: 1128-1137
12. Rowley JD (1973) A new consistent chromosome abnormality in chronic myelogenous leukaemia detected by quinacrine fluorescence and Giemsa staining. Nature 243: 290-293